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a b s t r a c t
Respiratory syncytial virus (RSV) nonstructural (NS) proteins 1 and 2 have multiple functions in
suppressing the innate immune response and modulating T helper cell subset differentiation. However,
little is known about the roles of NS proteins as independent virulence factors. We investigated the
effects of recombinant NS1- and NS2-expressing plasmids on the pathogenesis of murine respiratory
tissues and splenetic Foxp3þ regulatory T (Treg) cell distribution. Both NS proteins caused weight loss in
mice, and NS2 transfection resulted in a persistent weight loss. NS1 dramatically suppressed the
induction of interferon beta and interferon-induced GTP-binding protein Mx1. NS1 and NS2 demon-
strated different effects in regulating Treg cell differentiation; NS2 increased the proportion of Tregs,
whereas NS1 suppressed it. Inhibiting either NS1 or NS2 alleviated the pathology of lung tissues. Thus,
NS1 and NS2 are independent pathogenic factors and could be targets for therapeutic strategies in
treating RSV infection.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Respiratory syncytial virus (RSV) infection is commonly asso-
ciated with lower respiratory infections and the exacerbation of
airway hyper-responsiveness (AHR) in infants, leading to the
development of asthma in childhood or adolescence (Sigurs
et al., 2000; Openshaw et al., 2003; Mohapatra and Boyapalle,
2008). Despite the substantial health and economic burdens
caused by RSV infections, no safe and effective vaccine is available
currently (Schickli et al., 2009). Consequently, there is a substantial
need for effective and reliable vaccines and antiviral reagents.
The RSV genome includes 15.2 kb negative-sense RNA, from
which two small nonstructural (NS) proteins are translated,
known as NS1 and NS2, with 139 and 124 amino acid residues,
respectively (Collins et al., 2013). The NS proteins are not packaged
into mature virions, but are only expressed in infected cells, where
the mRNAs are relatively abundant because of the proximity of
their 30 ends to the promoter in the negative-stranded genome
(Bitko et al., 2007). The RSV NS proteins, especially NS1, are of
paramount importance for viral replication, and NS1- or NS2-
defective viruses are poorly infective (Jin et al., 2000; Teng et al.,
2000; Kong et al., 2007). Apart from being involved in viral
replication, the NS proteins also play a key role in subverting the
host's innate immune response by blocking type I interferon (IFN)
induction and signaling (Schlender et al., 2000; Bossert and
Conzelmann, 2002; Spann et al., 2004, 2005; Ramaswamy et al.,
2006; Swedan et al, 2009; Hastie et al., 2012). Therefore, they are
crucial molecules enabling the virus to escape from host surveil-
lance. NS1 and NS2 cooperate or act individually to inhibit the
induction of type I IFNs and IFN-stimulated genes (ISGs)
(Schlender et al., 2000; Lo et al., 2005; Swedan et al., 2009). The
NS proteins antagonize the activation of type I IFNs and ISGs by
interacting with retinoic acid-inducible gene-I (RIG-I) and Toll-like
receptor 3 (TLR3), two pattern-recognition receptors (PRRs) that
are able to recognize and respond to pathogen-associated mole-
cular patterns generated by viral infections (van Drunen and
Watkiss, 2012). NS1 inhibits RIG-I from binding to mitochondrial
antiviral signaling protein (MAVS) to hamper the MAVS–RIG-I
interaction required for IFN production (Boyapalle et al., 2012).
NS2 can also bind to RIG-I, but not to MAVS, which is involved in
downstream signaling for IFN production (Ling et al., 2009). Thus,
NS1 and NS2 play different roles in interfering with the host's
antiviral response signaling by acting at different steps. However,
it is still unclear whether NS proteins are associated directly with
host pathogenesis, and far less is known on whether they play an
independent role in the course of RSV-related illnesses.
Recurrent RSV infection in infancy is associated with the
development of asthma in subsequent life, while an early bias
towards immune tolerance renders infants more vulnerable to RSV
infection (Krishnamoorthy et al., 2012). Regulatory T cells (Tregs)
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are important for immune tolerance by suppressing unwarranted
immune responses to foreign antigens (Josefowicz and Rudensky,
2009; Hall et al., in press). They were initially recognized as the
CD4þT cell subsets that constitutively express the interleukin-2
receptor CD25 (Fontenot et al., 2003), which is controlled by
expression of the forkhead box protein 3 (Foxp3) transcription
factor (Hori et al., 2003; Khattri et al., 2003). NS proteins modulate
the differentiation and proliferation of T helper (Th) cell subsets.
Thus, NS1 inhibits the differentiation of T lymphocytes via mono-
ubiquitination to interacting proteins, while NS2 inhibits the
differentiation of Th2 and Th17 subsets through an ubiquitin–
proteasome pathway, which might be associated with increased
susceptibility to asthma after RSV infection (Qin et al., 2014). The
NS1 protein suppresses the proliferation and activation of protec-
tive Th cell populations (CD8þ T cells and Th17 cells), and
promotes the proliferation and activation of Th2 cells that can
enhance diseases caused by RSV (Munir et al., 2011). NS1, but not
NS2, impairs glucocorticoid-induced transactivation and contri-
butes to glucocorticoid resistance in cases of RSV infection
(Webster et al., 2014). RSV infection promotes epithelial cell
shedding via the action of NS2, which not only accelerates viral
clearance but also contributes to acute obstruction of distal
airways (Liesman et al., 2014). Acute RSV infection results in an
increase in the number of Tregs in the lung (Ruckwardt et al.,
2009; Fulton et al., 2010; Barik, 2013). However, it is currently
unclear whether most Tregs induced during RSV infection repre-
sent those activated in response to the release of self-antigens by
the death of virus-infected host epithelial cells (Barik, 2013). Given
this background, we speculate that NS proteins might act as
pathogenic factors in infancy by mediating Treg cell functions to
modulate the host's immune tolerance, which could be associated
with the development of allergies in later life.
Here, we tested the potential effects of NS1 and NS2 as
pathogenic factors, and investigated their effect on regulating
the induction of IFN-β and the interferon-stimulated gene product
GTP-binding protein Mx1, as well as the expression of mature
Foxp3þ Tregs in BALB/c mice. Our aim was to explore how RSV NS
proteins affect systematic pathogenesis in vivo.
Results
Recombinant RSV NS plasmids expressed in the mouse respiratory
tract
To check the expression efﬁcacy of NS plasmids in the mouse,
three different doses of plasmids per mouse (low 2 μg, medium
4 μg, and high 8 μg) were instilled intranasally, and antigens in
respiratory tissues were detected using immunohistochemistry.
The NS protein-positive cells were stained brown. Fig. 1a shows
the expression of pNS1 and pNS2 plasmids in mouse respiratory
tract tissues after transfection by instillation at the indicated times.
Both NS1-Flag and NS2-HA antigens were detected by 24 h after
instillation and were expressed continuously over 7 days. Antigen-
positive cells were located ﬁrst in the bronchiolar epithelium, and
then expanded to the alveoli, with the target proteins spread
almost completely over the cells. Pathological changes in lung
tissues caused by the different doses of plasmids were also
detected, and the numbers of antigen-positive cells increased
along with the dose of plasmid instilled (Fig. 1b). Evidently, these
three different doses of plasmids could express target genes
successfully; however, compared with the low-dose group, plas-
mids in the high-dose and medium-dose groups produced sig-
niﬁcantly more antigen-positive cells (po0.05), but these did not
increase with the time course. These results demonstrated that the
codon-deoptimized recombinant NS1 and NS2 plasmids were
expressed successfully and dose dependently in mouse respiratory
epithelia.
RSV NS proteins displayed pathogenic effects in mice
Based on the successful plasmid transfection model, the body
weights and lung histopathology of mice were documented after
instillation of plasmids to explore the pathogenic effect of NS
proteins on mice. The body weight was monitored daily post-
instillation. As shown in Fig. 2a and b, transfection of both pNS1
and pNS2 resulted in a weight decline of 5–10% compared with the
original weight in the ﬁrst 4 days, and the weight loss depended
signiﬁcantly on the plasmid dose instilled (po0.05). Compared
with the three pNS1 groups, in which the mouse body weight
rebounded from the 5th day p.i., the body weights of the high-
dose and medium-dose pNS2 treatment groups decreased persis-
tently, and the high-dose group declined to less than 80% of their
initial weight at day 7 p.i. Only the low-dose group of mice
recovered to their original weight at the end of the study period
(po0.05). Thus, the RSV NS1 and NS2 proteins are both patho-
genic leading to weight loss in mice, while NS2 demonstrated a
much more severe virulence than NS1. The respiratory tissues
were subjected to histopathology using H&E staining. As shown in
Fig. 2c, the lungs of mice transfected with NS plasmids manifested
typical inﬂammatory changes, primarily lymphocytic inﬁltrations,
supplemented with a few neutrophils and eosinophils. There was
perivascular edema and thickened or even ruptured alveolar walls.
Besides these features of inﬂammation, there were more bronch-
iolar luminal exudates containing necrotic cell debris compared
with the vehicle group (empty vector), also a sign of inﬂammation.
The BAL cells were collected for counting, and both pNS1 and
pNS2 caused inﬂammatory cell inﬂuxes. However, compared with
pNS1, pNS2 induced more neutrophils and lymphocytes, but fewer
eosinophils (Fig. 2d). This inﬂammatory cell inﬂux lasted for 9 days
p.i. and was correlated with the weight loss in the mice. Thus, both
NS1 and NS2 were crucial virulence factors causing respiratory
pathology, while NS2 had a stronger and longer impact.
NS proteins play different roles in interfering with the murine
respiratory tract innate antiviral response
The RSV NS proteins suppress both IFN induction and IFN-
inducible antiviral signaling in vitro (Swedan et al., 2009). To verify
the interaction of NS proteins in respiratory epithelia in vivo, mice
were instilled with 4 μg of plasmids and the lung tissues were
harvested at the indicated time points for the detection of IFN-β
and Mx1 mRNA expression levels using qRT-PCR. At 1, 3, 5, and
7 days p.i., pNS1 treatment suppressed IFN-β mRNA expression
over the entire period of observation (Fig. 3a). Unlike pNS1, pNS2
showed a suppressing effect only during the ﬁrst day, and a sharp
increase in IFN-β expression until day 7 p.i. A similar tendency was
observed in Mx1 mRNA expression (Fig. 3b). RIG-I is the main PRR
pathway through which RNA viruses induce IFN production, and
further affect the expression of SOCS1 in feedback regulation
(Hashimoto et al., 2009). To explore the potential function of NS
proteins in interfering with IFN-inducible signaling, western blot-
ting was performed to detect RIG-I and SOCS1 expression in
murine respiratory tracts. As shown in Fig. 3c, neither pNS1 nor
pNS2 had any effect on regulating the expression of RIG-I, but they
both upregulated SOCS1 expression on day 1 p.i. Unlike pNS2,
which induced an increase in SOCS1 expression at day 1 p.i., and
then declined to the original level at day 3, pNS1 treatment
produced a persistent upregulating effect throughout the follow-
ing days (po0.05). Although NS1 and NS2 suppress IFN-inducible
antiviral molecules in vitro, our results demonstrated that there
were different effects of two NS proteins on the induction of IFN-β
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and Mx1 in vivo. NS1 inhibited the induction of IFN and Mx1, and
upregulated SOCS1 expression, while NS2 mainly upregulated
SOCS1 at an early point and induced IFN-β at the end of the
observation time. These results were quite different from those of
previous studies in vitro or in vivo (Kotelkin et al., 2006), in which
NS1 and NS2 are the key molecules suppressing IFN-inducible
antiviral signaling, whereas in our study pNS2 actually induced
IFN-β expression at a later time post p.i., which was consistent
with SOCS1 expression.
NS proteins modulated the distribution of mouse Treg cells
Treg cells have a fundamental role in the establishment and
maintenance of immune tolerance, serving as a safeguard against
many self- and foreign antigens by suppressing unwarranted
immune responses. It is possible that NS proteins are released to
the extracellular milieu within the debris of dead cells, which
could be related to the disturbance of immune regulation. There-
fore, we investigated whether RSV NS proteins might have an
impact on murine immune tolerance. The percentages of
CD4þCD25þFoxp3þ Tregs in murine splenocytes were analyzed
by ﬂow-activated cell sorting (FACS) after the instillation of
plasmids. Fig. 4a shows the tricolor stained FACS plots of CD25
and Foxp3 expressions by murine splenic CD4þT cells. The
corresponding bar graphs are shown in Fig. 4b. At days 1 and
3 p.i., the percentages of CD25þFoxp3þ Tregs by CD4þ T cells
in the two NS plasmid transfection groups were signiﬁcantly
lower than in the vehicle control group (po0.05). However, from
day 5 p.i., the pNS2 group showed increased amounts of
CD4þCD25þFoxp3þ Tregs compared with pNS1 treatment,
which showed a continuous decrease to 7 days p.i. These results
imply that the early expression of NS1 and NS2 had different
effects on the differentiation of Treg cells.
NS genes are potential targets for the treatment of RSV infections
To evaluate the potential of NS genes as targets for the
treatment of RSV infections, we monitored the effects of inhibiting
NS1 and NS2 on pathogenesis among RSV-challenged mice.
Compared with the normal controls and UV-RSV, the mice
challenged with RSV strain A2 all showed a signiﬁcant weight
loss to 15% below their original levels (Fig. 5a) in the ﬁrst 3 days
p.i., and then gradually recovered to their original weight by day
7 p.i. When mice were pretreated with siRNA against either NS1 or
NS2 mRNAs 24 h prior to the challenge with RSV strain A2, the
body weight declined by 8% compared with their initial weight,
but began to rebound from the third day p.i., with a larger
recovery compared with the RSV group (po0.05). Indeed, at days
4 and 5 p.i., they even surpassed the weight of the control group,
with a ﬁnal increase of 5% compared with the initial weight,
indicating that the pretreatment of siRNAs against the two NS
genes protected the mice against severe RSV infection. In other
words, silencing of the RSV NS protein mRNAs partly decreased
the virulence of RSV. In contrast, UV-RSV, which did not contain
the NS1 or NS2 proteins, showed no virulence in mice. As shown in
Fig. 5b, edema and mucus inﬁltrations were reduced dramatically
in the lungs of mice pretreated with siRNA against NS1 or NS2, and
the inﬂammation of murine respiratory tract showed apparent
amelioration on days 3 and 5 p.i. compared with the mismatched
siRNA controls (mock). Moreover, the RSV antigen-positive cells in
Fig. 1. Immunohistochemistry of the respiratory tract in mice transfected with recombinant NS plasmids. (a) BALB/c mice (n¼5) were instilled intranasally with a medium
dose of plasmids (4 μg in 100 μl per mouse) containing pNS1, pNS2, and empty vector (vehicle), and then euthanized at days 1, 3, 5, and 7 post-insttillation (p.i.). The left lung
tissues with main bronchi were harvested for immunohistochemistry, and cells stained brown are antigen positive (40 objective). (b) Comparison of the proportions of
antigen-positive cells among the groups of mice administered three different doses of NS plasmids (low, medium, and high). The mean densities of positive cells were
measured using Image-Pro Plus software. Data are shown as the mean7SE. The experiment was performed three times with similar results, and the results of one
representative experiment are shown. *po0.05 vs. the low-dose group.
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siRNA-treated tissues were reduced compared with the RSV group
(Fig. 5c). Thus, siRNAs against NS1 and NS2 protected against RSV
pathogenesis characterized by weight loss and respiratory tract
pathology.
Discussion
Here, we found that recombinant RSV NS1 and NS2 proteins
both acted as crucial virulence factors in mouse respiratory tract
Fig. 2. (a, b) Body weight change of mice after transfection with different doses of pNS1 (a) or pNS2 (b). BALB/c mice were instilled intranasally with three different doses of
plasmids per mouse suspended in 100 μl aliquots: high (8 μg), medium (4 μg), and low (2 μg). They were weighed daily, and the body weight is expressed as the percentage
of the initial weight. Data are shown as the mean7SE. *po0.05 vs. vehicle control in the pNS1 group (a), and vs. medium- and high-dose pNS2 groups (b). (c, d) Histology of
the respiratory tract in mice transfected with recombinant NS plasmids (10 objective). (c) BALB/c mice (n¼5) were instilled intranasally with a high dose of plasmids and
then euthanized at days 3 and 5 p.i. The left lung tissues with main bronchi were harvested and ﬁxed in 10% neutral buffered formalin, dehydrated, embedded in parafﬁn
wax, and sections were stained with H&E (10 objective). (d) Total numbers of inﬂammatory cells were counted in BAL ﬂuid. The absolute numbers of total cells,
eosinophils, neutrophils, and lymphatic cells were determined.*po0.05 vs. vehicle control; #po0.05 NS1 vs. NS2 and vehicle control.
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pathogenesis, and caused weight loss and pulmonary edema as
well as inﬂammatory cell inﬁltrations in mice. However, NS1 and
NS2 functioned differently in regulating IFN-inducible antiviral
gene expressions: thus, NS1 suppressed IFN-β and Mx1 produc-
tion continuously, while NS2 suppressed them only brieﬂy and
upregulated their expression levels later. Moreover, NS proteins
also modulated murine Treg cell differentiation, which could
modulate the host's immune tolerance.
NS1 and NS2 are two of the most abundantly expressed
proteins in RSV-infected cells because their genes are located
proximal to the viral promoter region (Gotoh et al., 2001; Bitko
et al., 2007; Swedan et al., 2011). This region allows a robust
replication of the virus, and prevents the induction of host innate
antiviral signaling, enabling the viruses to escape immune sur-
veillance during their life circle (Swedan et al., 2009, 2011).
However, few studies have reported NS proteins as independent
pathogenic factors directly related to illness. To our knowledge,
this is the ﬁrst study to verify that the RSV NS proteins can cause
pulmonary damage and modulate a bias in murine immune
tolerance. Although NS1 and NS2 are not packaged into virion
particles, they can be released to the extracellular milieu along
with dead cell debris. Tissues containing abundant NS proteins
could be virulence factors leading to RSV infection. As shown here,
mice receiving the instillations of NS plasmids showed symptoms
similar to RSV infection, such as rufﬂed fur, decreased activity, and
drowsiness, among which weight loss is the most characteristic
manifestation (Cormier et al., 2010; Stokes et al., 2011). At the early
stage after plasmids were instilled, changes in behavior and
outward appearance predominated, and after the recovery of these
symptoms in 1 or 2 days, a decrease in body weight became the
main manifestation. Compared with the pNS1 groups, in which the
body weight began to rise again from day 5 p.i., pNS2 caused more
severe and long-lasting weight loss. These results demonstrated
that these two RSV NS proteins could cause pathogenesis and
pathological pulmonary changes independently of each other.
Another ﬁnding in our study was that NS1 and NS2 had different
effects on ISGs in murine respiratory tissues. NS proteins did not
show any effect on RIG-I expression, but NS1 suppressed IFN-β
and Mx1 mRNA expression levels; by contrast, NS2 suppressed
these only on the ﬁrst day and actually induced their expression at
day 7. These results are consistent with our previous results that
NS1 upregulated SOCS1 expression, which inhibits IFN-inducible
signaling (Xu et al., 2014), but NS2 showed an opposite effect on
IFN induction as well as SOCS1 expression. It is not yet clear why
NS2 upregulated the expressions of IFN-β and Mx1 later, as this
was not consistent with previous observations (Kotelkin et al.,
2006; Lo et al., 2005; Ling et al., 2009). One explanation could be
that our experiments, which were based on animal models in
which the upregulation effect was observed very late at day 7 p.i,
are different from those involving 24 h cell culture. The artiﬁcial
codon-deoptimized sequence with an extra tag could be another
possible explanation. However, this still implies that the NS-
related pathogenicity is not correlated to IFN induction and its
signaling activation.
The RSV NS proteins suppress IFN pathways by inhibiting or
degrading a number of signaling proteins, and thus could act as
essential virulence factors (Goswami et al., 2013). Moreover, NS2
might be a major contributor to the development of early
pathologies, and induces cell shedding as an important factor in
RSV pathogenesis. Thus, it acts by increasing the likelihood of
small airway obstruction, thereby promoting epithelial cell shed-
ding, which not only accelerates viral clearance but also contri-
butes to acute obstruction of the distal airways (Liesman et al.,
2014). In our study, the histopathology showed that NS2 caused
small amounts of respiratory tract edema and narrowing as well as
mucus inﬁltration, similar to the report of Liesman et al. Although
NS1 caused the same changes as NS2 in our study, to date there is
no evidence of NS1-related pathogenesis in general. Here, we
demonstrated that NS1 inhibited the expression levels of IFN and
the ISG Mx1 in vivo, as shown previously in vitro (Zheng et al.,
2015). It also promoted SOCS1 expression, which could result in a
bias in the Th1/Th2 ratio indirectly correlated with pathogenesis.
Deletion of the gene encoding NS2 attenuates its activity, and
our results support the strategy of developing live respiratory tract
virus vaccines in which the ability to inhibit the human innate
immune system is blocked (Wright et al., 2006). Overexpression of
RSV NS1, but not NS2, impairs glucocorticoid-induced transactiva-
tion. Viruses with deletion in the genes encoding either NS1 or
Fig. 3. The mRNA expression of IFN-β (a) and Mx1 (b) in murine lung tissues after transfection with recombinant RSV NS plasmids. Mice were euthanized at 1, 3, 5, and
7 days p.i. The right lung tissues were removed and homogenized. Total RNA was extracted and qRT-PCR was performed to determine the target mRNA expression levels.
Gene expression was normalized against β-actin gene expression as an internal control and fold change values were calculated relative to the sample of day 1 p.i. of empty
vector (vehicle) group assigned an arbitrary value of 1. Data are from three independent experiments and are shown as the mean7SE. *po0.05 vs. the controls; #po0.05 vs.
pNS2. (c) Effect of NS plasmids on the levels of RIG-I and SOCS1 in murine lung tissues. Mice (n¼4–5 mice per group) were sacriﬁced at 1, 3, 5, or 7 days p.i. with a medium
dose of plasmids. The right lung tissues were removed and homogenized; proteins were extracted for western blotting to evaluate the levels of RIG-I and SOCS1. The relative
densities of RIG-I and SOCS1 protein bands were normalized against β-actin controls. Fold changes were calculated relative to the sample of day 1 p.i. of the vehicle control
group assigned an arbitrary value of 1. The experiment was performed ﬁve times from three mice with similar results, and the results of one representative experiment are
shown. Data are shown as the mean7SE. *po0.05 vs. vehicle control.
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NS2, or both, are unable to repress glucocorticoid induction of the
glucocorticoid receptor-regulated gene. Moreover, inhibition of
these two proteins would also enhance glucocorticoid responsive-
ness besides enhancing host antiviral IFN responses (Webster
et al., 2014). Compared with pNS1, pNS2 caused severe weight
loss in the last few days p.i., which implies that NS2 had more
severe virulence than NS1. When mice were pretreated with siRNA
against NS genes, their body weight showed a moderate decrease
and then recovered. Thus, siRNAs against NS1 and NS2 protected
against RSV pathogenesis characterized by weight loss and
respiratory tract pathology, implying that the NS proteins could
be potential targets for therapies against RSV infection.
Foxp3 is a member of the forkhead or winged helix family of
transcription factors. It is a principal regulatory protein involved in
cell lineage commitment or developmental differentiation of
CD4þCD25þ Treg cells (Chatila et al., 2000; Fontenot et al.,
2003; Josefowicz and Rudensky, 2009; Josefowicz et al., 2012;
Lan et al., 2012; Dhuban et al., 2014). Treg cells are now widely
Fig. 4. CD4þCD25þFoxp3þ regulatory T cell (Treg) counts in splenocytes of mice transfected with plasmids. Mice (n¼5 per group) were euthanized at the given days p.i.
with a medium dose of plasmids. (a) Representative FACS plots of CD25 and Foxp3 expressions on splenic CD4þT cells at 1, 3, 5, and 7 days p.i. (b) The percentages of
CD4þCD25þFoxp3þ Tregs in the spleen were determined. Bars represent the mean7SE. The experiment was performed three times with similar results, and the results of
one representative experiment are shown. *po0.05 vs. vehicle control.
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accepted as crucial in regulating and suppressing the immune
system (Josefowicz and Rudensky, 2009). Lee et al. (2010) have
demonstrated that Tregs appear to dampen both innate and
adaptive immune responses, and in their absence, immunopathol-
ogy and RSV disease are enhanced and recovery is delayed,
underscoring the importance of Tregs in regulating virally induced
lung inﬂammation. Whether the RSV NS proteins are directly
associated with this phenomenon is still unclear. Therefore, we
performed this study using recombinant NS plasmids in the
absence of other viral proteins and determined their effect on
Treg cell distribution. After transfection with pNS2, there was
initially a decrease and then a gradual increase in the percentage
of Treg cells. NS1 suppressed the production of Treg cells. This
would promote the host's adaptive immunity, which might be
Fig. 5. (a) Body weight changes in mice after RSV infection. BALB/c mice (n¼5) were instilled intranasally with PBS, 1107 PFU/ml of RSV, or UV-irradiated RSV. Mice
pretreated with siRNA were instilled with single doses of 100 μl siNS1 or siNS2 24 h prior to RSV infection. All the mice were weighed daily, and their body weight was
expressed as the percentage of initial weight. Data are shown as the mean7SE. *po0.05 vs. RSV infection. (b, c) Immunohistochemistry of murine respiratory tract after
siRNA treatment and RSV infection. BALB/c mice (n¼5) were instilled with siRNA (100 pmol in 100 μl per mouse) against NS1 or NS2 24 h prior to RSV challenge, and then
euthanized at days 3 or 5 p.i. The left lung tissues with main bronchi were ﬁxed in 10% neutral buffered formalin, dehydrated, embedded in parafﬁn wax, and subjected to
standard histological techniques (H&E staining) or immunohistochemistry (10 objective).
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associated with Th2-type immune responses and the exacerbation
of AHR. In contrast, NS2 induced immune tolerance in these mice
by upregulating the production of Treg cells, which would increase
the vulnerability to recurrent respiratory infections.
In conclusion, we have demonstrated that RSV NS proteins had
apparent pathogenic effects on mice. NS1 played a more harmful
role by interrupting the host's innate immune response, while NS2
promoted the induction of Treg cells. Further studies on NS
proteins might lead to therapies against RSV infection and asso-
ciated diseases.
Materials and methods
Animals
All animal research was approved by the Animal Ethics Com-
mittee of the Medical Faculty of Wuhan University (Wuhan, Hubei,
PR China). Six- to 8-week-old speciﬁc-pathogen-free female BALB/
c mice were purchased from the Center for Animal Experiment,
ABSL-3 Laboratory of Wuhan University, maintained under
pathogen-free conditions and fed sterilized water and food ad
libitum in the same center.
Cells and viruses
Human A549 pulmonary epithelial cells were obtained from
the American Type Culture Collection (ATCC; Manassas, VA, USA)
and grown in Dulbecco's Modiﬁed Eagle's Medium supplemented
with 10% fetal bovine serum, 1% L-glutamine (with 100 U penicillin
and 100 U streptavidin/ml) at 37 1C in 5% CO2/95% humidiﬁed air.
The cells were passaged when grown to a 90% conﬂuence mono-
layer. The RSV A2 strain was from ATCC, propagated and puriﬁed
as described (Hashimoto et al., 2009), and snap-frozen until use.
The viral titer of plaque-forming unit (PFU) was determined by a
standard plaque titration assay on the A549 cells.
Short interfering RNA (siRNA)-mediated gene silencing in mice
Sequences of siRNAs targeting RSV A2 strain NS1 and NS2 mRNAs
(siNS1, siNS2) were designed and synthesized by Invitrogen Co.
(Shanghai, PR China) as follows: siNS1, 50-GUGAUUCAACAAUGAC-
CAAdTdT-30; and siNS2, 50-GACAUGAGACCGUUGUCACdTdT-30. The
siRNA inhibition efﬁciency was determined using quantitative reverse
transcription polymerase chain reaction (qRT-PCR) assays as described
(Zheng et al., in press). For animal experiments, 5 μl of 20 μM siNS1 or
siNS2 and 5 μl of Lipofectamine 2000 (Invitrogen Life Technologies,
Carlsbad, CA, USA) were each diluted in 45 μl of Opti-MEM I Reduced
SerumMedium (Gibco, Grand Island, NY, USA). The two dilutions were
then mixed and incubated at room temperature before transfection.
Mice were given single intranasal doses of 100 pmol of the siRNA mix
in 100 μl aliquots according to the manufacturer's instructions (Invi-
trogen Life Technologies).
Plasmid constitution and mouse treatments
The recombinant expression plasmids RSV NS1-Flag and NS2-
HA (pNS1, pNS2) were designed and synthesized by Invitrogen
(Invitrogen Co., PR China) according to the NS1 and NS2 open
reading frames of RSV A2 strain (GenBank Accession no.
AF035006) and codon deoptimization was artiﬁcially modiﬁed
for optimal expression in mammalian host cells (NS1 JQ900253.1
and NS2 JQ900254.1; Xu et al., 2014). For transfection, mice (n¼5
per group) were instilled intranasally with plasmids (100 μl)
complexed with Lipofectamine 2000 transfection reagent (Invitro-
gen Life Sciences) according to the manufacturer's instructions. For
viral infection, RSV A2 or UV-irradiated RSV was instilled intrana-
sally, and equal volumes of phosphate-buffered saline (PBS) or
Lipofectamine 2000 solution lacking vectors were instilled as
controls. The intranasal instillation was performed with the mice
under anesthesia with 8% chloral hydrate (400 mg/kg). Animals
were euthanized by dislocation of the cervical vertebrae, and the
lungs and spleen were harvested. The left lungs were ﬁxed in 4%
paraformaldehyde for histopathology and immunohistochemistry,
and the right lungs were stored at 80 1C prior to extraction of
RNA and cell proteins for qRT-PCR and western blotting. The
spleens were forced through a nylon mesh shortly after removal
for the preparation of single cell suspensions of splenocytes and
were analyzed by ﬂow cytometry using Mouse Regulatory T Cell
Staining kits (Cat. #88-8115, eBioscience, San Diego, CA).
Quantitative RT-PCR
Total lung RNA was extracted using Trizol Reagent (Invitrogen Life
Sciences) in accordance with the manufacturer's instructions. For each
RNA sample, 1 μg of RNA was reverse transcribed in a 20 μl reaction
mixture using M-MLV Reverse Transcription kits (Invitrogen Life
Sciences). qRT-PCR was performed using FastStart Universal SYBR
Green Master Mix (Roche, Mannheim, Germany) with 2.5 μl of cDNA
in a total volume of 25 μl of master mix. The reaction was conducted
in an Mxp 3000p Real-time Quantitative PCR Detection System
(Applied Biosystems, Foster City, CA, USA) under the following
conditions: predenaturation at 95 1C for 10 min followed by 40 cycles
of PCR (denaturation at 95 1C for 15 s, annealing at 60 1C for 60 s), and
a ﬁnal extension at 60 1C for 5 min. The experiments were performed
in triplicate, and the Ct value of each sample was normalized using β-
actin mRNA expression as an internal control. The relative expression
levels of target genes were calculated based on the difference between
the Ct values of the target genes and those of internal control genes,
calculated as 2ΔΔCt. The primers used for the ampliﬁcations were as
follows: mouse IFN-β, forward 50-CGTGGGAGATGTCCTCAACTG-30,
reverse 50-ATCTCTGCTCGGACCACCATC-30; mouse Mx1, forward 50-
GCCAGGACCAGGTTTACAAGG-30, reverse 50-TTTCAGGTGCTGGGT-
CATCTCA-30; β-actin, forward 50-GTGACGTTGACATCCGTAAAGA-30,
reverse 50-GTAACAGTCCGCCTAGAAGCAC-30.
Western blotting
For the analysis of whole cell lysates, proteins were extracted
from thawed lung homogenates using Cell Lysis buffer (Beyotime
Institute of Biotechnology, China) which consists of 20 mM Tris–
HCl (pH 7.5), 1% Triton X-100, 0.5% sodium deoxycholate, 10%
glycerol, 150 mM NaCl, 2 mM EDTA, 50 mM β-glycerophosphate,
2 mM Na3VO4, 10 mM NaF, 1 mM DTT and 1 mM phenylmethyl-
sulfonyl ﬂuoride. The protein concentration was determined using
protein assay kits (Beyotime Institute of Biotechnology, PR China).
Equivalent amounts of protein were separated by SDS-
polyacrylamide gel electrophoresis, transferred to PVDF mem-
branes (Millipore, Billerica, MA, USA), and blocked with 4% (w/v)
skim milk powder in buffer comprising 10 mM Tris–HCl (pH 7.5)
and 0.15 M NaCl with 0.5% (v/v) Tween 20 (TBST). The membranes
were washed with TBST and probed by incubation with primary
antibodies speciﬁc for suppression of cytokine signaling (SOCS)-1
and RIG-I (1:500, Cell Signaling Technology Inc., Danvers, MA,
USA) diluted to 4% (w/v). As a loading control, lysates were probed
with anti-β-actin antibodies (Cell Signaling Technology Inc.). The
membranes were washed and bound antibodies were detected by
secondary incubation with a horseradish peroxidase (HRP)-
coupled goat anti-rabbit antibody. The target bands were visua-
lized using ECL Plus Western Detection reagents (Beyotime Insti-
tute of Biotechnology) and exposed to BioMax X-ray ﬁlm (Kodak,
P. Yang et al. / Virology 485 (2015) 223–232230
Rochester, NY, USA). Band density was quantiﬁed using Image-Pro
Plus software (http://support.mediacy.com/ipp701.asp).
Pulmonary histopathology and immunohistochemistry
The left lung tissues were ﬁxed in 10% buffered formalin,
subsequently embedded in parafﬁn wax, and tissue sections were
stained with hematoxylin and eosin (H&E) to assess any histolo-
gical changes. For immunohistochemistry, the primary antibodies
for immunostaining directed at the NS1 and NS2 proteins were
speciﬁc for Flag-tags (#2368, DYKDDDDK Tag Antibody, Biotiny-
lated, Cell Signaling Technology) and HA-tags (#3724, C29F4, Cell
Signaling Technology), respectively. Immunostaining for RSV was
carried out using a goat anti-RSV polyclonal antibody (AB1128,
Millipore) as the primary antibody, and the secondary antibodies
were HRP-tagged rabbit anti-goat immunoglobulin (14-13-06, KPL,
Gaithersburg, MD, USA). Visualization was achieved using avidin-
peroxidase and diaminobenzidine. All immunostained sections
were counterstained with hematoxylin. Multiple sections from
each tissue block were analyzed using light microscopy. The
pictures were analyzed using Image-Pro Plus software (see above).
Cell processing and ﬂow cytometry
Single cell suspensions of splenocytes were prepared by forcing
through a 40 μm cell strainer followed by red blood cell lysis, and
then stained with ﬂuorescently tagged monoclonal antibodies
from eBioscience. These included anti-Mouse CD16/32, anti-
mouse CD4 FITC (RM4-5, 1:250), anti-mouse CD25 PE (PC61.5,
1:250), anti-mouse/rat Foxp3 PE-Cy5 (FJK-16s), rat IgG2a Isotype
Control PE-Cy5, and isotype controls for anti-CD4 (rat IgG2a,
cat.11-4321) and anti-CD25 (rat IgG1, Cat.12-4301). All the proce-
dures were carried out according to the manufacturer's instruc-
tions. Brieﬂy, cells were ﬁrst blocked with anti-mouse CD16/32
and then stained with anti-mouse CD4 FITC and anti-mouse CD25
PE, washed in cold Flow Cytometry Staining Buffer, ﬁxed using
ﬁxation/permeabilization working solution (eBioscience), and
stained with anti-mouse/rat Foxp3 PE-Cy5. Cells were analyzed
using a Cytomics FC 500 ﬂow cytometer (Beckmann Coulter,
Fullerton, CA, USA).
Bronchoalveolar lavage (BAL) cell classiﬁcation
Mouse BAL cells were collected from the extracted lungs by
inserting a syringe with a cannulated needle into the trachea and
ﬂushing 3 times with 1 ml of PBS supplemented with 12 mM
lidocaine powder (Sigma-Aldrich, St Louis, MO, USA). Lung lobes
were harvested and digested with collagenase XI (Sigma-Aldrich)
using a gentleMACs cell dissociator (Miltenyi Biotech, Bergisch
Gladbach, Germany) according to the manufacturer's protocol. To
count the cell numbers in the BAL ﬂuid, cells were transferred onto
a microscope slide using a Cytospin centrifuge, and slides were
stained with H&E. Cells were categorized as macrophages or
monocytes, lymphocytes, neutrophils, and eosinophils based on
their morphology and size using a light microscope (Zeiss) (Durant
et al., 2013).
Statistics
All experiments in this study were performed 3–4 times
independently. Data are shown as the mean7standard error
(SE) of the mean. Results between groups were compared using
one-way analysis of variance and statistical signiﬁcance was
assumed at po0.05.
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